Selected Publications

Academic Article

Year Title Altmetric
2023 Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.JCO Precision Oncology.  7:e2200505. 2023
2023 An Assessment of the Feasibility and Utility of an ACCC-ASCO Implicit Bias Training Program to Enhance Racial and Ethnic Diversity in Cancer Clinical Trials.Jco Oncology Practice.  OP2200378. 2023
2023 Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate CancerClinical Cancer Research.  29:50-59. 2023
2023 A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancerBreast Cancer Research and Treatment2023
2022 Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signalingNature Communications.  13. 2022
2022 An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinasesJCI Insight.  7. 2022
2022 Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.JCO Precision Oncology.  6:e2200165. 2022
2022 The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer CellsFrontiers in Oncology.  12. 2022
2022 Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research StatementJournal of Clinical Oncology.  111. 2022
2022 Poly(N-vinylpyrrolidone)- block-Poly(dimethylsiloxane)- block-Poly(N-vinylpyrrolidone) Triblock Copolymer Polymersomes for Delivery of PARP1 siRNA to Breast CancersACS Applied Bio Materials.  5:1670-1682. 2022
2022 Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+ Breast CancerCancers.  14. 2022
2022 18F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 InhibitionClinical Cancer Research.  28:327-337. 2022
2021 An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancerBreast Cancer Research.  23. 2021
2021 RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4+ T-cell-dependent antitumor immunity 2021
2021 Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast CancerFrontiers in Oncology.  11. 2021
2021 Anti-cd47 monoclonal antibody–drug conjugate: A targeted therapy to treat triple-negative breast cancersVaccines.  9. 2021
2021 Gene expression signature correlates with outcomes in metastatic renal cell carcinoma patients treated with everolimus alone or with a vascular disrupting agentMolecular Cancer Therapeutics.  20:1454-1461. 2021
2021 Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.JCO Precision Oncology.  5. 2021
2021 Targeted liposomal chemotherapies to treat triple-negative breast cancerCancers.  13. 2021
2021 The bet inhibitor JQ1 augments the antitumor efficacy of gemcitabine in preclinical models of pancreatic cancerCancers.  13. 2021
2021 A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinomaRadiotherapy and Oncology.  157:203-209. 2021
2021 PSPH promotes melanoma growth and metastasis by metabolic deregulation-mediated transcriptional activation of NR4A1Oncogene.  40:2448-2462. 2021
2021 Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapyActa Biotechnologica.  21:37-44. 2021
2021 Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancerSupportive Care in Cancer.  29:263-269. 2021
2021 Targeting DNA repair pathways to overcome cancer drug resistance 2021
2020 Obesity diminishes response to PD-1-based immunotherapies in renal cancerJournal for ImmunoTherapy of Cancer.  8. 2020
2020 TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related GenesJournal of Clinical Oncology.  38:4274-4282. 2020
2020 Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancyNature Communications.  11. 2020
2020 Osteoporosis screening using computed tomography for men with prostate cancer: results of a prospective studyArchives of Osteoporosis.  15. 2020
2020 Combining PARP and DNA-PK Inhibitors With Irradiation Inhibits HPV-Negative Head and Neck Cancer Squamous Carcinoma GrowthFrontiers in Genetics.  11. 2020
2020 CHK1/2 inhibitor prexasertib suppresses notch signaling and enhances cytotoxicity of cisplatin and radiation in head and neck squamous cell carcinomaMolecular Cancer Therapeutics.  19:1279-1288. 2020
2020 Randomized trial of weight loss in primary breast cancer: Impact on body composition, circulating biomarkers and tumor characteristicsInternational Journal of Cancer.  146:2784-2796. 2020
2020 Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progressionOncogene.  39:4077-4091. 2020
2020 Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1ROncogenesis.  9. 2020
2020 Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancerPLoS One.  15. 2020
2020 Combined targeting of mutant p53 and jumonji family histone demethylase augments therapeutic efficacy of radiation in H3K27M DIPGInternational Journal of Molecular Sciences.  21. 2020
2020 Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancerTherapeutic Advances in Medical Oncology.  12. 2020
2019 Combined Targeting of Mutant p53 and Jumonji Family Histone Demethylase Augments Therapeutic Efficacy of Radiation in H3K27M DIPG 2019
2019 Feasibility of Dose Escalating [18F]fluciclovine Positron Emission Tomography Positive Pelvic Lymph Nodes During Moderately Hypofractionated Radiation Therapy for High-Risk Prostate CancerAdvances in Radiation Oncology.  4:649-658. 2019
2019 The pros and cons of incorporating transcriptomics in the age of precision oncology 2019
2019 WNT pathway signaling is associated with microvascular injury and predicts kidney transplant failureAmerican Journal of Transplantation.  19:2833-2845. 2019
2019 Differential escape mechanisms in cetuximab-resistant head and neck cancer cellsBiochemical and Biophysical Research Communications.  517:36-42. 2019
2019 Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapiesGenes and Diseases.  6:232-246. 2019
2019 Early time-restricted feeding improves 24-hour glucose levels and affects markers of the circadian clock, aging, and autophagy in humansNutrients.  11. 2019
2019 The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitorsEBioMedicine.  44:419-430. 2019
2019 Patient Demographics and Referral Patterns for [F-18]Fluciclovine-PET Imaging at a Tertiary Academic Medical CenterJournal of the American College of Radiology.  16:315-320. 2019
2019 Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective TrialAdvances in Radiation Oncology.  4:90-95. 2019
2019 Targeting DNA repair in precision medicineAdvances in protein chemistry and structural biology.  115:135-155. 2019
2018 The antitumor effects of entinostat in ovarian cancer require adaptive immunityCancer.  124:4657-4666. 2018
2018 First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibitionJournal of the National Comprehensive Cancer Network : JNCCN.  16:1166-1170. 2018
2018 Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic TargetsEuropean urology focus.  4:733-736. 2018
2018 Reply to "phase II prospective randomized trial of weight loss prior to radical prostatectomyProstate Cancer and Prostatic Diseases.  21:293-294. 2018
2018 Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinomaMolecular Cancer Research.  16:813-824. 2018
2018 Trastuzumab-resistant HER2 þ breast cancer cells retain sensitivity to poly (adp-ribose) polymerase (parp) inhibitionMolecular Cancer Therapeutics.  17:921-930. 2018
2018 Stereotactic Radiosurgery for Prostate Cancer Following Magnetic Resonance Imaging Directed Biopsy: A Multidisciplinary Approach with Case Examples.Cureus.  10:e2524. 2018
2018 Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466Oncotarget.  9:19459-19459. 2018
2018 ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damageJournal of Biological Chemistry.  293:984-994. 2018
2018 JQ1 induces DNA damage and apoptosis, and inhibits tumor growth in a patient-derived xenograft model of cholangiocarcinomaMolecular Cancer Therapeutics.  17:107-118. 2018
2017 Non-coding MIR491 is associated with less EGFr expression and greater radiosensitivity in human head and neck cancer cell linesAnnals of Oncology.  28:x6. 2017
2017 Subcutaneous adipose tissue characteristics and the risk of biochemical recurrence in men with high-risk prostate cancerUrologic Oncology: seminars and original investigations.  35:663.e15-663.e21. 2017
2017 The impact of DNA repair pathways in cancer biology and therapyCancers.  9. 2017
2017 DNA repair deregulation in discrete prostate cancer lesions identified on multi-parametric MRI and targeted by MRI/ultrasound fusion-guided biopsyOncotarget.  8:68038-68046. 2017
2017 DNA repair deregulation in discrete prostate cancer lesions identified on multi-parametric MRI and targeted by MRI/ultrasound fusion-guided biopsy.Oncotarget.  8:68038-68046. 2017
2017 Implementation and utilization of the molecular tumor board to guide precision medicine.Oncotarget.  8:57845-57854. 2017
2017 A step towards predicting checkpoint inhibitor response in kidney cancer 2017
2017 Common data elements for clinical research in mitochondrial disease: a National Institute for Neurological Disorders and Stroke projectJournal of Inherited Metabolic Disease.  40:403-414. 2017
2017 Combining Chk1/2 inhibition with cetuximab and radiation enhances in vitro and in vivo cytotoxicity in head and neck squamous cell carcinomaMolecular Cancer Therapeutics.  16:591-600. 2017
2017 CT measures of bone mineral density and muscle mass can Be used to predict noncancer death in men with prostate cancerRadiology.  282:475-483. 2017
2017 Let-7 status is crucial for PARP1 expression in HER2-overexpressing breast tumorsMolecular Cancer Research.  15:340-347. 2017
2017 MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell linesOncology Letters.  13:1216-1222. 2017
2017 Poly(ADP-ribose) polymerase activity and inhibition in cancerSeminars in Cell and Developmental Biology.  63:144-153. 2017
2017 DNA-PkCS expression in oropharyngeal squamous cell carcinoma: Correlations with human papillomavirus status and recurrence after transoral robotic surgery 2017
2017 Implementation and utilization of the molecular tumor board to guide precision medicineOncotarget.  8:57845-57854. 2017
2017 Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targetsOncotarget.  8:21710-21718. 2017
2017 Presurgical weight loss affects tumour traits and circulating biomarkers in men with prostate cancerBritish Journal of Cancer.  117:1303-1313. 2017
2016 Potential biomarkers for radiosensitivity in head and neck cancersAnnals of translational medicine.  4. 2016
2016 Notch signaling activation is associated with patient mortality and increased FGF1-mediated invasion in squamous cell carcinoma of the oral cavityMolecular Cancer Research.  14:883-891. 2016
2016 Kinase gene expression profiling of metastatic clear cell renal cell carcinoma tissue identifies potential new therapeutic targetsPLoS One.  11. 2016
2016 Current and emerging clinical applications of multispectral optoacoustic tomography (MSOT) in oncologyClinical Cancer Research.  22:3432-3439. 2016
2016 The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft modelsOncogene.  35:833-845. 2016
2016 Niclosamide and its analogs are potent inhibitors of Wnt/ß- catenin, mTOR and STAT3 signaling in ovarian cancerOncotarget.  7:86803-86815. 2016
2016 Pelvic radiotherapy versus radical prostatectomy with limited lymph node sampling for high-grade prostate adenocarcinomaProstate Cancer.  2016. 2016
2016 Prostate Radiotherapy in the Era of Advanced Imaging and Precision MedicineProstate Cancer.  2016. 2016
2015 Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutritionSeminars in Cancer Biology.  35:S5-S24. 2015
2015 Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 InhibitionBMC Cancer.  15. 2015
2015 Effect of African-American Race on Tumor Recurrence after Radical Cystectomy for Urothelial Carcinoma of the BladderClinical Genitourinary Cancer.  13:469-475. 2015
2015 The protective effect of p16 INK4a in oral cavity carcinomas: p16 Ink4A dampens tumor invasion-integrated analysis of expression and kinomics pathwaysModern Pathology.  28:631-653. 2015
2015 PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancersBreast Cancer Research and Treatment.  150:569-579. 2015
2015 Targeting the effector domain of the myristoylated alanine rich C-kinase substrate enhances lung cancer radiation sensitivityInternational Journal of Oncology.  46:1079-1088. 2015
2015 Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥3 cm 2015
2015 DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinomaOncotarget.  6:26995-27007. 2015
2015 Designing a broad-spectrum integrative approach for cancer prevention and treatmentSeminars in Cancer Biology.  35:S276-S304. 2015
2015 Synthetic sickness with molecularly targeted agents against the egfr pathwayCancer Drug Discovery and Development.  83:381-412. 2015
2014 Reduced radiation tolerance of penile structures associated with dose-escalated hypofractionated prostate radiotherapyUrology.  84:1383-1388. 2014
2014 Different rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapyRadiation Oncology.  9. 2014
2014 Concentration calibration of urine biomarkers for diagnosis improvement of ovarian cancerInternational Journal of Bio-Science and Bio-Technology.  6:65-72. 2014
2014 Epigenetic inactivation of DNA repair in breast cancerCancer Letters.  342:213-222. 2014
2014 Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage 2014
2014 An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancerGynecologic Oncology.  134:331-337. 2014
2014 Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolinesRadiotherapy and Oncology.  111:468-474. 2014
2014 PSA response to neoadjuvant androgen deprivation is an independent prognostic marker and may identify patients who benefit from treatment escalationUrologic Oncology: seminars and original investigations.  32:687-693. 2014
2014 The Smad7-Skp2 complex orchestrates Myc stability, impacting on the cytostatic effect of TGF-βJournal of Cell Science.  127:411-421. 2014
2013 Beyond DNA repair: Additional functions of PARP-1 in cancerFrontiers in Oncology.  3 NOV. 2013
2013 PARP-1: Friend or foe of DNA damage and repair in tumorigenesis?Cancers.  5:943-958. 2013
2013 Segmentation editing improves efficiency while reducing inter-expert variation and maintaining accuracy for normal brain tissues in the presence of space-occupying lesionsPhysics in Medicine and Biology.  58:4071-4097. 2013
2013 BRCA1-Ku80 protein interaction enhances end-joining fidelity of chromosomal double-strand breaks in the G1 phase of the cell cycleJournal of Biological Chemistry.  288:8966-8976. 2013
2013 Discussion of PARP inhibitors in cancer therapyPharmaceutical Patent Analyst.  2:755-766. 2013
2013 Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancerClinical Cancer Research.  19:170-182. 2013
2012 Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibitionCancer Research.  72:5547-5555. 2012
2012 Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer CellsPLoS One.  7. 2012
2012 HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repairCancer Research.  72:4796-4806. 2012
2012 The intersection between DNA damage response and cell death pathways 2012
2012 Biomarkers to assess the targeting of DNA repair pathways to augment tumor response to therapyCurrent Molecular Medicine.  12:788-803. 2012
2012 Kinomic profiling approach identifies Trk as a novel radiation modulatorRadiotherapy and Oncology.  103:380-387. 2012
2012 MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for gliomaClinical Cancer Research.  18:3030-3041. 2012
2012 Assaying DNA damage in hippocampal neurons using the comet assay.Journal of Visualized Experiments2012
2012 Hypofractionated Prostate Radiotherapy with or without Conventionally Fractionated Nodal Irradiation: Clinical Toxicity Observations and Retrospective Daily Dosimetry.Prostate Cancer.  2012:546794. 2012
2011 Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiationRadiotherapy and Oncology.  101:183-189. 2011
2011 Cetuximab augments cytotoxicity with poly (ADP-Ribose) polymerase inhibition in head and neck cancerPLoS One.  6. 2011
2011 p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damageCancer Research.  71:5546-5557. 2011
2011 Comparison of manual and automatic segmentation methods for brain structures in the presence of space-occupying lesions: A multi-expert studyPhysics in Medicine and Biology.  56:4557-4577. 2011
2011 Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinomaRadiotherapy and Oncology.  99:339-343. 2011
2011 The poly(ADP-ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapyRadiotherapy and Oncology.  99:331-338. 2011
2011 Glycogen synthase kinase 3β inhibition enhances repair of DNA double-strand breaks in irradiated hippocampal neuronsNeuro-Oncology.  13:459-470. 2011
2011 Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors.Frontiers in Molecular Neuroscience.  4:47. 2011
2010 BRCA1 16 years later: DNA damage-induced BRCA1 shuttling 2010
2010 DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulationCancer Research.  70:6258-6267. 2010
2010 Reduction of Dose Delivered to Organs at Risk in Prostate Cancer Patients via Image-Guided Radiation Therapy 2010
2009 Evolution of clinical trials in head and neck cancer 2009
2009 Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PK-dependent repair in miceJournal of Clinical Investigation.  119:1124-1135. 2009
2009 Refractory lympho-epithelial carcinoma of the nasopharynx: a case report illustrating a protracted clinical course.Head and Neck Oncology.  1:18. 2009
2008 Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cellsCancer Research.  68:9141-9146. 2008
2007 Autophagy signaling in cancer and its potential as novel target to improve anticancer therapyDrug Resistance Updates.  10:135-143. 2007
2007 The role of mTOR inhibition in augmenting radiation induced autophagyTechnology in Cancer Research and Treatment.  6:443-447. 2007
2005 Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic varietyJournal of Clinical Oncology.  23:6730-6738. 2005
2004 Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21CIP1 levels in androgen-independent human prostate cancer cellsOncogene.  23:5513-5522. 2004
2003 Vitamin D Inhibits G1 to S Progression in LNCaP Prostate Cancer Cells through p27Kip1 Stabilization and Cdk2 Mislocalization to the CytoplasmJournal of Biological Chemistry.  278:46862-46868. 2003
2002 Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancerMolecular and Cellular Endocrinology.  186:69-79. 2002
1999 Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesisCancer Research.  59:3855-3860. 1999


Year Title Altmetric
2019 Combining Chk1/2 inhibition with radiation in head and neck cancer.  301-316. 2019
2015 Interaction of Chemotherapy and Radiation.  63-79.e4. 2015

Research Overview

  • Many cancer therapies attack cellular DNA to cause DNA damage. The DNA double strand break (DSB) is the most critical form of DNA damage that induces both normal and cancer cell death if left unrepaired. My research interests involve the targeting of DNA repair pathways to enhance the therapeutic ratio. We aim to discover novel strategies to augment DNA repair pathways to specifically protect normal cells from DNA damage while reducing DNA repair capacity to convert cancer cells to become more susceptible to DNA damaging agents. Ultimately, we hope to translate our work into the clinic to deferentially treat cancer while sparing normal cells to maintain quality of life.

    Keywords - nanostring, profiling, DNA damage, DNA repair, EGFR, cancer, PARP, apoptosis, brain, protection, GSK3
  • Principal Investigator On

  • Biomarkers for Detection of Renal Cell Carcinoma  awarded by American Cancer Society, Inc.
  • Can Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling Induce Synthetic Lethality with Poly (ADP-Ribose) Polymerase Inhibition (PARPi) by Generating a DNA Repair Defect?  awarded by Kimmel (Sidney) Foundation for Cancer Research
  • Comprehensive Cancer Center Core Support Grant - Experimental Therapeutics Program  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Experimental Therapeutics Program  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Experimental Therapeutics Program  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Support Grant - Experimental Therapeutics  awarded by National Cancer Institute/NIH/DHHS
  • DNA Repair Independent Mechanisms of HER2+ Tumor Sensitivity to PARP Inhibition  awarded by Komen (Susan G.) Breast Cancer Foundation
  • Elevated NF-kB Signaling in Breast Cancers of African American Women  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • Exploiting TNBC Vulnerabilities Via Rationally Combined Therapies  awarded by American Association for Cancer Research
  • HER2 Overexpression Confers Susceptibility to PARP Inhibition  awarded by American Association for Cancer Research
  • Mechanisms by Which GSK3B Inhibition Enhances Nonhomologous End-Joining Repair  awarded by GABRIELLE'S ANGEL FOUNDATION
  • Mutant p53 Reactivation as a Targeted Approach for Radio-Sensitization of Malignancies Harboring Disruptive Mutations in TP53 Gene.  awarded by Radiological Society of North America
  • Phase IB Trial of Radium-223 and Niraparib in Patients with Castrate Resistant Prostate Cancer  awarded by THOMAS JEFFERSON UNIVERSITY - NEW
  • Private Grant  awarded by ABBOTT LABORATORIES
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by CLOVIS ONCOLOGY
  • Private Grant  awarded by CLOVIS ONCOLOGY
  • Private Grant  awarded by ASTRAZENECA AB
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by PUMA BIOTECHNOLOGY, INC.
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by ARCUS BIOSCIENCES INC
  • Private Grant  awarded by PUMA BIOTECHNOLOGY, INC.
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by ELEVATION ONCOLOGY INC.
  • Private Grant  awarded by STRATA ONCOLOGY
  • Private Grant  awarded by STRATA ONCOLOGY
  • Targeting Homology-Directed Recombinational Repair (HDR) of Chromosomal Breaks to Sensitize Prostate Cancer Cells to Poly (ADP-Ribose) Polymerase (PARP) Inhibition  awarded by DOD - Department of Defense
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology
  • UAB 1846: A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes  awarded by Johns Hopkins University
  • Investigator On

  • A New Paradigm: Using PARP Inhibitors to Treat HER2+ Breast Cancer  awarded by Komen (Susan G.) Breast Cancer Foundation
  • A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer  awarded by University of Florida^
  • A Targeted Mitochondrial Luminoptogenetic Gene Therapy to Treat Triple Negative Breast Cancer  awarded by DOD - Department of Defense
  • American Society of Clinical Oncology survey on COVID19 in Oncology Registry  awarded by American Society of Clinical Oncology
  • Clinical and Molecular Biomarkers of Endpoints in Pediatric Renal Transplantation  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP)  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Integrating Basic Science And Community Outreach And Engagement To Bridge The Transdisciplinary Cancer Research Continuum  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Deciphering How Esco2 Loss Acts as a Penetrance Modifier  awarded by National Cancer Institute/NIH/DHHS
  • Developing Novel Combination Therapies for Pancreatic Cancer  awarded by National Cancer Institute/NIH/DHHS
  • Developing Therapy for the Treatment of Cholangiocarcinoma  awarded by National Cancer Institute/NIH/DHHS
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • Integrating Genomic Risk Assessment for Chronic Disease Management in a Diverse Population  awarded by National Human Genome Research Institute/NIH/DHHS
  • Mathematical Modeling and Molecular Imaging to Maximize Response While Minimizing Toxicities from Systemic Therapies in Preclinical Models of Breast Cancer  awarded by National Cancer Institute/NIH/DHHS
  • Mechanism of Ultraviolet Radiation Induced Immune Tolerance  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • ONE SHOT - Single Shot Radiotherapy for Localized Prostate Cancer - A Multicenter, Single Arm, Phase I/II Trial  awarded by GENEVA UNIVERSITY HOSPITAL
  • Private Grant  awarded by Novartis Pharma AG
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by SUCAMPO PHARMACEUTICALS
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC.
  • Private Grant  awarded by IMAGINAB^
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by RUBIUS THERAPEUTICS INC
  • Private Grant  awarded by EMD SERONO
  • Private Grant  awarded by CELCUITY
  • Quantitative Imaging To Personalize Therapy in Her2 Breast Cancer  awarded by American Cancer Society, Inc.
  • RAD 2001 (2012-0825): Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck  awarded by UNIVERSITY OF TEXAS (M.D. ANDERSON CANCER CENTER)
  • RTOG Foundation Master Service Agreement for Participation in Foundation Research: RTOG 3501 Tryhard: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb) for Non-HPV Locally Advanced Head and Neck Cancer with Concurrent Chemoradiation  awarded by American College of Radiology
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University
  • TBCRC 050 UAB 17112-A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer  awarded by Johns Hopkins University
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • Using the Genomic Profile of High Intermediate Risk Endometrial Cancer Patients to Differentiate Patients at High Risk of Recurrence from the Majority with Low Risk of Recurrence  awarded by FOUNDATION FOR GYNECOLOGIC ONCOLOGY
  • Education And Training

  • Mount Sinai Hospital, Internship
  • Vanderbilt University Medical Center, Residency
  • Doctor of Medicine, University of Miami 2005
  • Doctor of Philosophy in Molecular Pharmacology, University of Miami 2005
  • Full Name

  • Eddy Yang